A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Related studies linked through entity extraction aliases.